Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | terminated | Phase 2 | 7 | Incyte CorporationINDUSTRY | 16 | Nov 4, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY |
| 33 |
| Oct 30, 2025 |
| clinicaltrials |
| NCT02677896 | A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)(ARCHES) | completed | Phase 3 | 1,150 | Astellas Pharma Global Development, Inc.INDUSTRY | 24 | Oct 24, 2025 | clinicaltrials |
| NCT02107703 | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer(MONARCH 2) | active not recruiting | Phase 3 | 669 | Eli Lilly and CompanyINDUSTRY | 20 | Oct 21, 2025 | clinicaltrials |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer(LIBRETTO-431) | active not recruiting | Phase 3 | 261 | Eli Lilly and CompanyINDUSTRY | 26 | Oct 21, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT05307328 | SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome(RESCUE) | completed | Phase 2 | 26 | Sparrow PharmaceuticalsINDUSTRY | 3 | Oct 8, 2025 | clinicaltrials |
| NCT05564052 | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma(VEGA) | completed | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 7, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy | active not recruiting | Phase 3 | 187 | ExelixisINDUSTRY | 25 | Sep 25, 2025 | clinicaltrials |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | completed | Phase 3 | 331 | Genzyme, a Sanofi CompanyINDUSTRY | 24 | Sep 24, 2025 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT03596866 | A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer(ALTA-3) | completed | Phase 3 | 248 | TakedaINDUSTRY | 20 | Sep 12, 2025 | clinicaltrials |
| NCT00532155 | A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer(VITAL) | completed | Phase 3 | 913 | SanofiINDUSTRY | 32 | Sep 10, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT04308590 | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas(GRADIENT) | completed | Phase 3 | 137 | Corcept TherapeuticsINDUSTRY | 9 | Sep 4, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT02748460 | Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting(Premium) | completed | — | 1,527 | PregLem SAINDUSTRY | 16 | Sep 2, 2025 | clinicaltrials |
| NCT00777036 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib | completed | Phase 2 | 133 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 29, 2025 | clinicaltrials |
| NCT02195479 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 706 | Janssen Research & Development, LLCINDUSTRY | 24 | Aug 22, 2025 | clinicaltrials |
| NCT06828224 | Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® L in Correcting Moderate or Severe Nasolabial Folds | completed | N/A | 34 | Quantum Beauty KozmetikINDUSTRY | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(STELLAR-305) | active not recruiting | Phase 2 / Phase 3 | 600 | ExelixisINDUSTRY | 26 | Aug 17, 2025 | clinicaltrials |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 243 | GlaxoSmithKlineINDUSTRY | 12 | Aug 8, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT02684006 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | completed | Phase 3 | 886 | PfizerINDUSTRY | 21 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT03697109 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome(GRACE) | completed | Phase 3 | 152 | Corcept TherapeuticsINDUSTRY | 11 | Jul 16, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT04740424 | FS222 First in Human Study in Patients With Advanced Malignancies | recruiting | Phase 1 | 260 | invoX Pharma LimitedINDUSTRY | 7 | Jul 1, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT03739710 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 175 | GlaxoSmithKlineINDUSTRY | 12 | Jun 15, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 265 | ImmunoGenesisINDUSTRY | 10 | May 16, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | recruiting | — | 1,000 | Associazione Angela Serra per la ricerca sul cancroOTHER | 4 | May 6, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 101 | Bristol-Myers SquibbINDUSTRY | 8 | Apr 20, 2025 | clinicaltrials |
| NCT06903663 | The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting(MANIFEST-HCC) | not yet recruiting | — | 100 | Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian FodorOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06931847 | SUNRISE Aims to Create a Comprehensive, Engaging, and Sustainable Digital Health Promotion Program That Not Only Addresses Immediate Health Behaviours But Also Instils Lifelong Healthy Habits Among Adolescents. It is a Unique, Digitally Enhanced Program Combining Different Digital Solutions With New(SUNRISE_2) | not yet recruiting | — | 4,000 | Biobizkaia Health Research InstituteOTHER_GOV | 8 | Apr 17, 2025 | clinicaltrials |
| NCT06922201 | The SUNRISE Project is Dedicated to Enhancing Primary Cancer Prevention Among Adolescents in Europe by Leveraging Innovative Digital Tools and Methodologies. SmartCoach, Developed by Swiss Research Institute for Public Health and Addiction (ISGF), is a Mobile Phone-based Life-skills Training Program(SUNRISE_1) | not yet recruiting | N/A | 3,500 | Biobizkaia Health Research InstituteOTHER_GOV | 8 | Apr 10, 2025 | clinicaltrials |
| NCT05421650 | Therapeutic Effect of Surgical Debulking of Metastatic Lymph Nodes in Cervical Cancer Stage IIICr | recruiting | N/A | 240 | CHA UniversityOTHER | 5 | Apr 9, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials